{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "SARS-CoV-2", "antiviral agents", "assay development", "infection"]], "OtherAbstract": [], "SpaceFlightMission": [], "InvestigatorList": [], "CitationSubset": ["IM"], "OtherID": [], "GeneralNote": [], "PMID": "38474097", "DateCompleted": {"Year": "2024", "Month": "03", "Day": "14"}, "DateRevised": {"Year": "2024", "Month": "03", "Day": "15"}, "Article": {"Language": ["eng"], "ELocationID": ["2850", "10.3390/ijms25052850"], "ArticleDate": [{"Year": "2024", "Month": "03", "Day": "01"}], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "25", "Issue": "5", "PubDate": {"Year": "2024", "Month": "Mar", "Day": "01"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Development of Fluorescence-Based Assays for Key Viral Proteins in the SARS-CoV-2 Infection Process and Lifecycle.", "Abstract": {"AbstractText": ["Since the appearance of SARS-CoV-2 in 2019, the ensuing COVID-19 (Corona Virus Disease 2019) pandemic has posed a significant threat to the global public health system, human health, life, and economic well-being. Researchers worldwide have devoted considerable efforts to curb its spread and development. The latest studies have identified five viral proteins, spike protein (Spike), viral main protease (3CLpro), papain-like protease (PLpro), RNA-dependent RNA polymerase (RdRp), and viral helicase (Helicase), which play crucial roles in the invasion of SARS-CoV-2 into the human body and its lifecycle. The development of novel anti-SARS-CoV-2 drugs targeting these five viral proteins holds immense promise. Therefore, the development of efficient, high-throughput screening methodologies specifically designed for these viral proteins is of utmost importance. Currently, a plethora of screening techniques exists, with fluorescence-based assays emerging as predominant contenders. In this review, we elucidate the foundational principles and methodologies underpinning fluorescence-based screening approaches directed at these pivotal viral targets, hoping to guide researchers in the judicious selection and refinement of screening strategies, thereby facilitating the discovery and development of lead compounds for anti-SARS-CoV-2 pharmaceuticals."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Deng", "ForeName": "Mingzhenlong", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Zhang", "ForeName": "Chuang", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Yan", "ForeName": "Wanli", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Chen", "ForeName": "Lei", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Provincial Key Laboratory of Pharmaceutics, School of Pharmacy, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "He", "ForeName": "Bin", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Basic Medical Science, Guizhou Medical University, Guiyang 550004, China."}], "LastName": "Li", "ForeName": "Yan", "Initials": "Y"}], "GrantList": [{"GrantID": "[2020]4Y206 and GCC [2022]030-1, CXTD [2022]005, ZK [2022]035", "Agency": "Guizhou Science and Technology Department of China", "Country": ""}, {"GrantID": "81960628 and 82160655", "Agency": "National Natural Science Foundation of China", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Viral Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "EC 3.4.-", "NameOfSubstance": "Peptide Hydrolases"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "COVID-19"}, {"QualifierName": [], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "Viral Proteins"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": [], "DescriptorName": "Peptide Hydrolases"}], "CoiStatement": "The authors declare no conflicts of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Weiss S.R., Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev. 2005;69:635\u2013664. doi: 10.1128/MMBR.69.4.635-664.2005.", "ArticleIdList": ["10.1128/MMBR.69.4.635-664.2005", "PMC1306801", "16339739"]}, {"Citation": "Verstrepen K., Baisier L., De Cauwer H. Neurological manifestations of COVID-19, SARS and MERS. Acta. Neurol. Belg. 2020;120:1051\u20131060. doi: 10.1007/s13760-020-01412-4.", "ArticleIdList": ["10.1007/s13760-020-01412-4", "PMC7303437", "32562214"]}, {"Citation": "Liu J., Xie W., Wang Y., Xiong Y., Chen S., Han J., Wu Q. A comparative overview of COVID-19, MERS and SARS: Review article. Int. J. Surg. 2020;81:1\u20138. doi: 10.1016/j.ijsu.2020.07.032.", "ArticleIdList": ["10.1016/j.ijsu.2020.07.032", "PMC7382925", "32730205"]}, {"Citation": "Jiang H., Yang P., Zhang J. Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds with One Stone. Front. Chem. 2022;10:822785. doi: 10.3389/fchem.2022.822785.", "ArticleIdList": ["10.3389/fchem.2022.822785", "PMC8905519", "35281561"]}, {"Citation": "Xie X., Muruato A.E., Zhang X., Lokugamage K.G., Fontes-Garfias C.R., Zou J., Liu J., Ren P., Balakrishnan M., Cihlar T., et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat. Commun. 2020;11:5214. doi: 10.1038/s41467-020-19055-7.", "ArticleIdList": ["10.1038/s41467-020-19055-7", "PMC7567097", "33060595"]}, {"Citation": "Zheng L., Zhang L., Huang J., Nandakumar K.S., Liu S., Cheng K. Potential treatment methods targeting 2019-nCoV infection. Eur. J. Med. Chem. 2020;205:112687. doi: 10.1016/j.ejmech.2020.112687.", "ArticleIdList": ["10.1016/j.ejmech.2020.112687", "PMC7385720", "32771797"]}, {"Citation": "Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141\u2013154. doi: 10.1038/s41579-020-00459-7.", "ArticleIdList": ["10.1038/s41579-020-00459-7", "PMC7537588", "33024307"]}, {"Citation": "Coronavirus (COVID-19) Deaths.  [(accessed on 7 December 2023)].  Available online:  https://ourworldindata.org/covid-deaths#what-is-the-cumulative-number-of-confirmed-deaths."}, {"Citation": "Yang H., Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol. 2021;19:685\u2013700. doi: 10.1038/s41579-021-00630-8.", "ArticleIdList": ["10.1038/s41579-021-00630-8", "PMC8447893", "34535791"]}, {"Citation": "Larue R.C., Xing E., Kenney A.D., Zhang Y., Tuazon J.A., Li J., Yount J.S., Li P.K., Sharma A. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2. Bioconjug. Chem. 2021;32:215\u2013223. doi: 10.1021/acs.bioconjchem.0c00664.", "ArticleIdList": ["10.1021/acs.bioconjchem.0c00664", "PMC7784661", "33356169"]}, {"Citation": "Taibe N.S., Kord M.A., Badawy M.A., Shytaj I.L., Elhefnawi M.M. Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. Ther. Adv. Respir. Dis. 2022;16:17534666221132736. doi: 10.1177/17534666221132736.", "ArticleIdList": ["10.1177/17534666221132736", "PMC9597285", "36282077"]}, {"Citation": "Gilmutdinova I.R., Yakovlev M.Y., Eremin P.S., Fesun A.D. Prospects of plasmapheresis for patients with severe COVID-19. Eur. J. Transl. Myol. 2020;30:9165. doi: 10.4081/ejtm.2020.9165.", "ArticleIdList": ["10.4081/ejtm.2020.9165", "PMC7582395", "33117508"]}, {"Citation": "Sheng W.H., Ko W.C., Huang Y.C., Hsueh P.R. SARS-CoV-2 and COVID-19. J. Microbiol. Immunol. Infect. 2020;53:363\u2013364. doi: 10.1016/j.jmii.2020.03.033.", "ArticleIdList": ["10.1016/j.jmii.2020.03.033", "PMC7194915", "32303481"]}, {"Citation": "Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T., Zhang Z., Wu Z., et al. Molecular Architecture of the SARS-CoV-2 Virus. Cell. 2020;183:730\u2013738.e13. doi: 10.1016/j.cell.2020.09.018.", "ArticleIdList": ["10.1016/j.cell.2020.09.018", "PMC7474903", "32979942"]}, {"Citation": "Harrison A.G., Lin T., Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020;41:1100\u20131115. doi: 10.1016/j.it.2020.10.004.", "ArticleIdList": ["10.1016/j.it.2020.10.004", "PMC7556779", "33132005"]}, {"Citation": "Naqvi A.A.T., Fatima K., Mohammad T., Fatima U., Singh I.K., Singh A., Atif S.M., Hariprasad G., Hasan G.M., Hassan M.I. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim. Biophys. Acta Mol. Basis Dis. 2020;1866:165878. doi: 10.1016/j.bbadis.2020.165878.", "ArticleIdList": ["10.1016/j.bbadis.2020.165878", "PMC7293463", "32544429"]}, {"Citation": "Li G., Hilgenfeld R., Whitley R., De Clercq E. Therapeutic strategies for COVID-19: Progress and lessons learned. Nat. Rev. Drug. Discov. 2023;22:449\u2013475. doi: 10.1038/s41573-023-00672-y.", "ArticleIdList": ["10.1038/s41573-023-00672-y", "PMC10113999", "37076602"]}, {"Citation": "Amin S.A., Banerjee S., Gayen S., Jha T. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors? Eur. J. Med. Chem. 2021;215:113294. doi: 10.1016/j.ejmech.2021.113294.", "ArticleIdList": ["10.1016/j.ejmech.2021.113294", "PMC7880840", "33618158"]}, {"Citation": "Girgis A.S., Panda S.S., Kariuki B.M., Bekheit M.S., Barghash R.F., Aboshouk D.R. Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2. Molecules. 2023;28:6603. doi: 10.3390/molecules28186603.", "ArticleIdList": ["10.3390/molecules28186603", "PMC10537473", "37764378"]}, {"Citation": "Liu C., Boland S., Scholle M.D., Bardiot D., Marchand A., Chaltin P., Blatt L.M., Beigelman L., Symons J.A., Raboisson P., et al. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development. Antivir. Res. 2021;187:105020. doi: 10.1016/j.antiviral.2021.105020.", "ArticleIdList": ["10.1016/j.antiviral.2021.105020", "PMC7839511", "33515606"]}, {"Citation": "Zumla A., Chan J.F., Azhar E.I., Hui D.S., Yuen K.Y. Coronaviruses\u2014Drug discovery and therapeutic options. Nat. Rev. Drug. Discov. 2016;15:327\u2013347. doi: 10.1038/nrd.2015.37.", "ArticleIdList": ["10.1038/nrd.2015.37", "PMC7097181", "26868298"]}, {"Citation": "Cecon E., Dam J., Jockers R. Detection of SARS-CoV-2 spike protein binding to ACE2 in living cells by TR-FRET. STAR Protoc. 2022;3:101024. doi: 10.1016/j.xpro.2021.101024.", "ArticleIdList": ["10.1016/j.xpro.2021.101024", "PMC8606263", "34841271"]}, {"Citation": "Gkogkou E., Barnasas G., Vougas K., Trougakos I.P. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators. Redox Biol. 2020;36:101615. doi: 10.1016/j.redox.2020.101615.", "ArticleIdList": ["10.1016/j.redox.2020.101615", "PMC7311357", "32863223"]}, {"Citation": "Meng W., Guo S., Cao S., Shuda M., Robinson-McCarthy L.R., McCarthy K.R., Shuda Y., Paniz Mondolfi A.E., Bryce C., Grimes Z., et al. Development and characterization of a new monoclonal antibody against SARS-CoV-2 NSP12 (RdRp) J. Med. Virol. 2023;95:e28246. doi: 10.1002/jmv.28246.", "ArticleIdList": ["10.1002/jmv.28246", "PMC9874566", "36271490"]}, {"Citation": "Tian L., Qiang T., Liang C., Ren X., Jia M., Zhang J., Li J., Wan M., YuWen X., Li H., et al. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic. Eur. J. Med. Chem. 2021;213:113201. doi: 10.1016/j.ejmech.2021.113201.", "ArticleIdList": ["10.1016/j.ejmech.2021.113201", "PMC7826122", "33524687"]}, {"Citation": "Rathnayake A.D., Zheng J., Kim Y., Perera K.D., Mackin S., Meyerholz D.K., Kashipathy M.M., Battaile K.P., Lovell S., Perlman S., et al. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice. Sci. Transl. Med. 2020;12:eabc5332. doi: 10.1126/scitranslmed.abc5332.", "ArticleIdList": ["10.1126/scitranslmed.abc5332", "PMC7574915", "32747425"]}, {"Citation": "Adedeji A.O., Sarafianos S.G. Antiviral drugs specific for coronaviruses in preclinical development. Curr. Opin. Virol. 2014;8:45\u201353. doi: 10.1016/j.coviro.2014.06.002.", "ArticleIdList": ["10.1016/j.coviro.2014.06.002", "PMC4195804", "24997250"]}, {"Citation": "Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q., Zhang L., et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581:215\u2013220. doi: 10.1038/s41586-020-2180-5.", "ArticleIdList": ["10.1038/s41586-020-2180-5", "32225176"]}, {"Citation": "Ziebuhr J., Snijder E.J., Gorbalenya A.E. Virus-encoded proteinases and proteolytic processing in the Nidovirales. Pt 4J. Gen. Virol. 2000;81:853\u2013879. doi: 10.1099/0022-1317-81-4-853.", "ArticleIdList": ["10.1099/0022-1317-81-4-853", "10725411"]}, {"Citation": "Aiello T.F., Garcia-Vidal C., Soriano A. Antiviral drugs against SARS-CoV-2. Rev. Esp. Quimioter. 2022;35((Suppl. 3)):10\u201315. doi: 10.37201/req/s03.03.2022.", "ArticleIdList": ["10.37201/req/s03.03.2022", "PMC9717461", "36285850"]}, {"Citation": "Pozzi C., Vanet A., Francesconi V., Tagliazucchi L., Tassone G., Venturelli A., Spyrakis F., Mazzorana M., Costi M.P., Tonelli M. Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective. J. Med. Chem. 2023;66:3664\u20133702. doi: 10.1021/acs.jmedchem.2c01229.", "ArticleIdList": ["10.1021/acs.jmedchem.2c01229", "PMC10005815", "36857133"]}, {"Citation": "Zhuo L.S., Wang M.S., Yang J.F., Xu H.C., Huang W., Shang L.Q., Yang G.F. Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. Top. Curr. Chem. 2021;379:23. doi: 10.1007/s41061-021-00335-9.", "ArticleIdList": ["10.1007/s41061-021-00335-9", "PMC8061463", "33886017"]}, {"Citation": "Luttens A., Gullberg H., Abdurakhmanov E., Vo D.D., Akaberi D., Talibov V.O., Nekhotiaeva N., Vangeel L., De Jonghe S., Jochmans D., et al. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses. J. Am. Chem. Soc. 2022;144:2905\u20132920. doi: 10.1021/jacs.1c08402.", "ArticleIdList": ["10.1021/jacs.1c08402", "PMC8848513", "35142215"]}, {"Citation": "Shen J.X., Du W.W., Xia Y.L., Zhang Z.B., Yu Z.F., Fu Y.X., Liu S.Q. Identification of and Mechanistic Insights into SARS-CoV-2 Main Protease Non-Covalent Inhibitors: An In-Silico Study. Int. J. Mol. Sci. 2023;24:4237. doi: 10.3390/ijms24044237.", "ArticleIdList": ["10.3390/ijms24044237", "PMC9959744", "36835648"]}, {"Citation": "Vanhulle E., Stroobants J., Provinciael B., Camps A., Noppen S., Maes P., Vermeire K. SARS-CoV-2 Permissive glioblastoma cell line for high throughput antiviral screening. Antivir. Res. 2022;203:105342. doi: 10.1016/j.antiviral.2022.105342.", "ArticleIdList": ["10.1016/j.antiviral.2022.105342", "PMC9113983", "35595082"]}, {"Citation": "To T.L., Li X., Shu X. Spying on SARS-CoV-2 with Fluorescent Tags and Protease Reporters. Viruses. 2023;15:2005. doi: 10.3390/v15102005.", "ArticleIdList": ["10.3390/v15102005", "PMC10612051", "37896782"]}, {"Citation": "Joseph J., Rameshan B. Advanced Biosensors for Virus Detection. Academic Press; Cambridge, MA, USA: 2022. Fluorescence-based biosensors for SARS-CoV-2 viral infection diagnostics; pp. 279\u2013303."}, {"Citation": "Abian O., Ortega-Alarcon D., Jimenez-Alesanco A., Ceballos-Laita L., Vega S., Reyburn H.T., Rizzuti B., Velazquez-Campoy A. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int. J. Biol. Macromol. 2020;164:1693\u20131703. doi: 10.1016/j.ijbiomac.2020.07.235.", "ArticleIdList": ["10.1016/j.ijbiomac.2020.07.235", "PMC7395220", "32745548"]}, {"Citation": "Mangiavacchi F., Botwina P., Menichetti E., Bagnoli L., Rosati O., Marini F., Fonseca S.F., Abenante L., Alves D., Dabrowska A., et al. Seleno-Functionalization of Quercetin Improves the Non-Covalent Inhibition of M(pro) and Its Antiviral Activity in Cells against SARS-CoV-2. Int. J. Mol. Sci. 2021;22:7048. doi: 10.3390/ijms22137048.", "ArticleIdList": ["10.3390/ijms22137048", "PMC8268238", "34208928"]}, {"Citation": "Li C., Zhou H., Guo L., Xie D., He H., Zhang H., Liu Y., Peng L., Zheng L., Lu W., et al. Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2. J. Transl. Med. 2022;20:314. doi: 10.1186/s12967-022-03501-9.", "ArticleIdList": ["10.1186/s12967-022-03501-9", "PMC9281089", "35836239"]}, {"Citation": "Cannalire R., Stefanelli I., Cerchia C., Beccari A.R., Pelliccia S., Summa V. SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells. Int. J. Mol. Sci. 2020;21:5707. doi: 10.3390/ijms21165707.", "ArticleIdList": ["10.3390/ijms21165707", "PMC7460888", "32784899"]}, {"Citation": "Ergin E., Dogan A., Parmaksiz M., El\u00e7in A.E., El\u00e7in Y.M. Time-Resolved Fluorescence Resonance Energy Transfer [TR-FRET] Assays for Biochemical Processes. Curr. Pharm. Biotechnol. 2016;17:1222\u20131230. doi: 10.2174/1389201017666160809164527.", "ArticleIdList": ["10.2174/1389201017666160809164527", "27604358"]}, {"Citation": "Cecon E., Burridge M., Cao L., Carter L., Ravichandran R., Dam J., Jockers R. SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET. Cell Chem. Biol. 2022;29:74\u201383.e4. doi: 10.1016/j.chembiol.2021.06.008.", "ArticleIdList": ["10.1016/j.chembiol.2021.06.008", "PMC8249686", "34246414"]}, {"Citation": "Kaur A., Kaur P., Ahuja S. Forster resonance energy transfer (FRET) and applications thereof. Anal. Methods. 2020;12:5532\u20135550. doi: 10.1039/D0AY01961E.", "ArticleIdList": ["10.1039/D0AY01961E", "33210685"]}, {"Citation": "Suh J.S., Kim H.S., Kim T.J. Development of a SARS-CoV-2-derived receptor-binding domain-based ACE2 biosensor. Sens. Actuators B Chem. 2021;334:129663. doi: 10.1016/j.snb.2021.129663.", "ArticleIdList": ["10.1016/j.snb.2021.129663", "PMC7885701", "33612970"]}, {"Citation": "Dixon A.S., Schwinn M.K., Hall M.P., Zimmerman K., Otto P., Lubben T.H., Butler B.L., Binkowski B.F., Machleidt T., Kirkland T.A., et al. NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. ACS Chem. Biol. 2016;11:400\u2013408. doi: 10.1021/acschembio.5b00753.", "ArticleIdList": ["10.1021/acschembio.5b00753", "26569370"]}, {"Citation": "Yang X., Liu L., Hao Y., So E., Emami S.S., Zhang D., Gong Y., Sheth P.M., Wang Y. A Bioluminescent Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and In Vitro. Viruses. 2021;13:1055. doi: 10.3390/v13061055.", "ArticleIdList": ["10.3390/v13061055", "PMC8227885", "34199601"]}, {"Citation": "Azad T., Singaravelu R., Fekete E.E.F., Taha Z., Rezaei R., Arulanandam R., Boulton S., Diallo J.S., Ilkow C.S., Bell J.C. SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition. Biosens. Bioelectron. 2021;180:113122. doi: 10.1016/j.bios.2021.113122.", "ArticleIdList": ["10.1016/j.bios.2021.113122", "PMC7921772", "33706157"]}, {"Citation": "Xu M., Pradhan M., Gorshkov K., Petersen J.D., Shen M., Guo H., Zhu W., Klumpp-Thomas C., Michael S., Itkin M., et al. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry. SLAS Discov. 2022;27:86\u201394. doi: 10.1016/j.slasd.2021.12.005.", "ArticleIdList": ["10.1016/j.slasd.2021.12.005", "PMC8720380", "35086793"]}, {"Citation": "Yang J., Xiao Y., Lidsky P.V., Wu C.T., Bonser L.R., Peng S., Garcia-Knight M.A., Tassetto M., Chung C.I., Li X., et al. Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2. Nat. Microbiol. 2023;8:121\u2013134. doi: 10.1038/s41564-022-01288-5.", "ArticleIdList": ["10.1038/s41564-022-01288-5", "PMC9831272", "36604514"]}, {"Citation": "Haga K., Takai-Todaka R., Sawada A., Katayama K. Luciferase-based quantification of membrane fusion induced by SARS-CoV-2 S protein. Genes Cells. 2022;27:537\u2013543. doi: 10.1111/gtc.12945.", "ArticleIdList": ["10.1111/gtc.12945", "PMC9347681", "35488742"]}, {"Citation": "Yin X., Chen L., Yuan S., Liu L., Gao Z. A robust high-throughput fluorescent polarization assay for the evaluation and screening of SARS-CoV-2 fusion inhibitors. Bioorg. Chem. 2021;116:105362. doi: 10.1016/j.bioorg.2021.105362.", "ArticleIdList": ["10.1016/j.bioorg.2021.105362", "PMC8457910", "34598089"]}, {"Citation": "Legare S., Heide F., Bailey-Elkin B.A., Stetefeld J. Improved SARS-CoV-2 main protease high-throughput screening assay using a 5-carboxyfluorescein substrate. J. Biol. Chem. 2022;298:101739. doi: 10.1016/j.jbc.2022.101739.", "ArticleIdList": ["10.1016/j.jbc.2022.101739", "PMC8849842", "35182525"]}, {"Citation": "Kronenberger T., Laufer S.A., Pillaiyar T. COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease. Drug Discov. Today. 2023;28:103579. doi: 10.1016/j.drudis.2023.103579.", "ArticleIdList": ["10.1016/j.drudis.2023.103579", "PMC10074736", "37028502"]}, {"Citation": "Tian D., Liu Y., Liang C., Xin L., Xie X., Zhang D., Wan M., Li H., Fu X., Liu H., et al. An update review of emerging small-molecule therapeutic options for COVID-19. Biomed. Pharmacother. 2021;137:111313. doi: 10.1016/j.biopha.2021.111313.", "ArticleIdList": ["10.1016/j.biopha.2021.111313", "PMC7857046", "33556871"]}, {"Citation": "Ullrich S., Nitsche C. SARS-CoV-2 Papain-Like Protease: Structure, Function and Inhibition. Chembiochem. 2022;23:e202200327. doi: 10.1002/cbic.202200327.", "ArticleIdList": ["10.1002/cbic.202200327", "PMC9538446", "35993805"]}, {"Citation": "Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A., Schulz L., Widera M., Mehdipour A.R., Tascher G., et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;587:657\u2013662. doi: 10.1038/s41586-020-2601-5.", "ArticleIdList": ["10.1038/s41586-020-2601-5", "PMC7116779", "32726803"]}, {"Citation": "Sayaf A.M., Ahmad H., Aslam M.A., Ghani S.A., Bano S., Yousafi Q., Suleman M., Khan A., Yeoh K.K., Wei D.Q. Pharmacotherapeutic Potential of Natural Products to Target the SARS-CoV-2 PLpro Using Molecular Screening and Simulation Approaches. Appl. Biochem. Biotechnol. 2023;195:6959\u20136978. doi: 10.1007/s12010-023-04466-1.", "ArticleIdList": ["10.1007/s12010-023-04466-1", "PMC10037394", "36961512"]}, {"Citation": "Gao H., Dai R., Su R. Computer-aided drug design for the pain-like protease (PL(pro)) inhibitors against SARS-CoV-2. Biomed. Pharmacother. 2023;159:114247. doi: 10.1016/j.biopha.2023.114247.", "ArticleIdList": ["10.1016/j.biopha.2023.114247", "PMC9841087", "36689835"]}, {"Citation": "Froggatt H.M., Heaton B.E., Heaton N.S. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL (pro) Reporter Assay. J. Virol. 2020;94:e01265-20. doi: 10.1128/JVI.01265-20.", "ArticleIdList": ["10.1128/JVI.01265-20", "PMC7592234", "32843534"]}, {"Citation": "Kim Y., Lovell S., Tiew K.C., Mandadapu S.R., Alliston K.R., Battaile K.P., Groutas W.C., Chang K.O. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J. Virol. 2012;86:11754\u201311762. doi: 10.1128/JVI.01348-12.", "ArticleIdList": ["10.1128/JVI.01348-12", "PMC3486288", "22915796"]}, {"Citation": "Zhu W., Xu M., Chen C.Z., Guo H., Shen M., Hu X., Shinn P., Klumpp-Thomas C., Michael S.G., Zheng W. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening. ACS Pharmacol. Transl. Sci. 2020;3:1008\u20131016. doi: 10.1021/acsptsci.0c00108.", "ArticleIdList": ["10.1021/acsptsci.0c00108", "PMC7507806", "33062953"]}, {"Citation": "Rawson J.M.O., Duchon A., Nikolaitchik O.A., Pathak V.K., Hu W.S. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL (pro) Inhibitors. Viruses. 2021;13:173. doi: 10.3390/v13020173.", "ArticleIdList": ["10.3390/v13020173", "PMC7911889", "33498923"]}, {"Citation": "O\u2019Brien A., Chen D.Y., Hackbart M., Close B.J., O\u2019Brien T.E., Saeed M., Baker S.C. Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor. Virology. 2021;556:73\u201378. doi: 10.1016/j.virol.2021.01.010.", "ArticleIdList": ["10.1016/j.virol.2021.01.010", "PMC7837110", "33548599"]}, {"Citation": "Kilianski A., Mielech A.M., Deng X., Baker S.C. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors. J. Virol. 2013;87:11955\u201311962. doi: 10.1128/JVI.02105-13.", "ArticleIdList": ["10.1128/JVI.02105-13", "PMC3807373", "23986593"]}, {"Citation": "Capasso C., Nocentini A., Supuran C.T. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses. Expert Opin. Ther. Pat. 2021;31:309\u2013324. doi: 10.1080/13543776.2021.1857726.", "ArticleIdList": ["10.1080/13543776.2021.1857726", "33246378"]}, {"Citation": "Mathieu C., Touret F., Jacquemin C., Janin Y.L., Nougairede A., Brailly M., Mazelier M., Decimo D., Vasseur V., Hans A., et al. A Bioluminescent 3CL(Pro) Activity Assay to Monitor SARS-CoV-2 Replication and Identify Inhibitors. Viruses. 2021;13:1814. doi: 10.3390/v13091814.", "ArticleIdList": ["10.3390/v13091814", "PMC8473059", "34578395"]}, {"Citation": "Ma C., Sacco M.D., Xia Z., Lambrinidis G., Townsend J.A., Hu Y., Meng X., Szeto T., Ba M., Zhang X., et al. Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay. ACS Cent. Sci. 2021;7:1245\u20131260. doi: 10.1021/acscentsci.1c00519.", "ArticleIdList": ["10.1021/acscentsci.1c00519", "PMC8265724", "34341772"]}, {"Citation": "Smith E., Davis-Gardner M.E., Garcia-Ordonez R.D., Nguyen T.T., Hull M., Chen E., Baillargeon P., Scampavia L., Strutzenberg T., Griffin P.R., et al. High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2. SLAS Discov. 2020;25:1152\u20131161. doi: 10.1177/2472555220963667.", "ArticleIdList": ["10.1177/2472555220963667", "PMC7550789", "33043784"]}, {"Citation": "Yan H., Liu Z., Yan G., Liu X., Liu X., Wang Y., Chen Y. A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors. Virology. 2022;574:18\u201324. doi: 10.1016/j.virol.2022.07.006.", "ArticleIdList": ["10.1016/j.virol.2022.07.006", "PMC9287753", "35870326"]}, {"Citation": "Sokolinskaya E.L., Putlyaeva L.V., Polinovskaya V.S., Lukyanov K.A. Genetically Encoded Fluorescent Sensors for SARS-CoV-2 Papain-like Protease PLpro. Int. J. Mol. Sci. 2022;23:7826. doi: 10.3390/ijms23147826.", "ArticleIdList": ["10.3390/ijms23147826", "PMC9318946", "35887174"]}, {"Citation": "Shehzadi K., Saba A., Yu M., Liang J. Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2. Top. Curr. Chem. 2023;381:22. doi: 10.1007/s41061-023-00432-x.", "ArticleIdList": ["10.1007/s41061-023-00432-x", "37318607"]}, {"Citation": "Shannon A., Le N.T., Selisko B., Eydoux C., Alvarez K., Guillemot J.C., Decroly E., Peersen O., Ferron F., Canard B. Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antivir. Res. 2020;178:104793. doi: 10.1016/j.antiviral.2020.104793.", "ArticleIdList": ["10.1016/j.antiviral.2020.104793", "PMC7151495", "32283108"]}, {"Citation": "Bekheit M.S., Panda S.S., Girgis A.S. Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2. Eur. J. Med. Chem. 2023;252:115292. doi: 10.1016/j.ejmech.2023.115292.", "ArticleIdList": ["10.1016/j.ejmech.2023.115292", "PMC10023213", "36965227"]}, {"Citation": "Bertolin A.P., Weissmann F., Zeng J., Posse V., Milligan J.C., Canal B., Ulferts R., Wu M., Drury L.S., Howell M., et al. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase. Biochem. J. 2021;478:2425\u20132443. doi: 10.1042/BCJ20210200.", "ArticleIdList": ["10.1042/BCJ20210200", "PMC8286815", "34198323"]}, {"Citation": "Kim Y.G., Yoo J.S., Kim J.H., Kim C.M., Oh J.W. Biochemical characterization of a recombinant Japanese encephalitis virus RNA-dependent RNA polymerase. BMC Mol. Biol. 2007;8:59. doi: 10.1186/1471-2199-8-59.", "ArticleIdList": ["10.1186/1471-2199-8-59", "PMC1934914", "17623110"]}, {"Citation": "Niyomrattanakit P., Chen Y.L., Dong H., Yin Z., Qing M., Glickman J.F., Lin K., Mueller D., Voshol H., Lim J.Y., et al. Inhibition of dengue virus polymerase by blocking of the RNA tunnel. J. Virol. 2010;84:5678\u20135686. doi: 10.1128/JVI.02451-09.", "ArticleIdList": ["10.1128/JVI.02451-09", "PMC2876596", "20237086"]}, {"Citation": "Kocabas F., Turan R.D., Aslan G.S. Fluorometric RdRp assay with self-priming RNA. Virus Genes. 2015;50:498\u2013504. doi: 10.1007/s11262-015-1187-8.", "ArticleIdList": ["10.1007/s11262-015-1187-8", "25749997"]}, {"Citation": "Bai X., Sun H., Wu S., Li Y., Wang L., Hong B. Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay. Front. Immunol. 2022;13:844749. doi: 10.3389/fimmu.2022.844749.", "ArticleIdList": ["10.3389/fimmu.2022.844749", "PMC9021610", "35464436"]}, {"Citation": "Lee J.C., Tseng C.K., Chen K.J., Huang K.J., Lin C.K., Lin Y.T. A cell-based reporter assay for inhibitor screening of hepatitis C virus RNA-dependent RNA polymerase. Anal. Biochem. 2010;403:52\u201362. doi: 10.1016/j.ab.2010.04.004.", "ArticleIdList": ["10.1016/j.ab.2010.04.004", "20382106"]}, {"Citation": "Min J.S., Kim G.W., Kwon S., Jin Y.H. A Cell-Based Reporter Assay for Screening Inhibitors of MERS Coronavirus RNA-Dependent RNA Polymerase Activity. J. Clin. Med. 2020;9:2399. doi: 10.3390/jcm9082399.", "ArticleIdList": ["10.3390/jcm9082399", "PMC7465106", "32727069"]}, {"Citation": "Uppal T., Tuffo K., Khaiboullina S., Reganti S., Pandori M., Verma S.C. Screening of SARS-CoV-2 antivirals through a cell-based RNA-dependent RNA polymerase (RdRp) reporter assay. Cell Insight. 2022;1:100046. doi: 10.1016/j.cellin.2022.100046.", "ArticleIdList": ["10.1016/j.cellin.2022.100046", "PMC9239919", "37192863"]}, {"Citation": "Min J.S., Kwon S., Jin Y.H. SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System. Biomedicines. 2021;9:996. doi: 10.3390/biomedicines9080996.", "ArticleIdList": ["10.3390/biomedicines9080996", "PMC8392292", "34440200"]}, {"Citation": "Sommers J.A., Loftus L.N., Jones M.P., 3rd, Lee R.A., Haren C.E., Dumm A.J., Brosh R.M., Jr. Biochemical analysis of SARS-CoV-2 Nsp13 helicase implicated in COVID-19 and factors that regulate its catalytic functions. J. Biol. Chem. 2023;299:102980. doi: 10.1016/j.jbc.2023.102980.", "ArticleIdList": ["10.1016/j.jbc.2023.102980", "PMC9897874", "36739951"]}, {"Citation": "White M.A., Lin W., Cheng X. Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase. J. Phys. Chem. Lett. 2020;11:9144\u20139151. doi: 10.1021/acs.jpclett.0c02421.", "ArticleIdList": ["10.1021/acs.jpclett.0c02421", "PMC7571306", "33052685"]}, {"Citation": "Halma M.T.J., Wever M.J.A., Abeln S., Roche D., Wuite G.J.L. Therapeutic potential of compounds targeting SARS-CoV-2 helicase. Front. Chem. 2022;10:1062352. doi: 10.3389/fchem.2022.1062352.", "ArticleIdList": ["10.3389/fchem.2022.1062352", "PMC9763700", "36561139"]}, {"Citation": "Berta D., Badaoui M., Martino S.A., Buigues P.J., Pisliakov A.V., Elghobashi-Meinhardt N., Wells G., Harris S.A., Frezza E., Rosta E. Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design. Chem. Sci. 2021;12:13492\u201313505. doi: 10.1039/D1SC02775A.", "ArticleIdList": ["10.1039/D1SC02775A", "PMC8528070", "34777769"]}, {"Citation": "Marx S.K., Mickolajczyk K.J., Craig J.M., Thomas C.A., Pfeffer A.M., Abell S.J., Carrasco J.D., Franzi M.C., Huang J.R., Kim H.C., et al. Observing inhibition of the SARS-CoV-2 helicase at single-nucleotide resolution. Nucleic Acids Res. 2023;51:9266\u20139278. doi: 10.1093/nar/gkad660.", "ArticleIdList": ["10.1093/nar/gkad660", "PMC10516658", "37560916"]}, {"Citation": "Adedeji A.O., Singh K., Calcaterra N.E., DeDiego M.L., Enjuanes L., Weiss S., Sarafianos S.G. Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrob. Agents Chemother. 2012;56:4718\u20134728. doi: 10.1128/AAC.00957-12.", "ArticleIdList": ["10.1128/AAC.00957-12", "PMC3421890", "22733076"]}, {"Citation": "Zeng J., Weissmann F., Bertolin A.P., Posse V., Canal B., Ulferts R., Wu M., Harvey R., Hussain S., Milligan J.C., et al. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase. Biochem. J. 2021;478:2405\u20132423. doi: 10.1042/BCJ20210201.", "ArticleIdList": ["10.1042/BCJ20210201", "PMC8286831", "34198322"]}]}], "History": [{"Year": "2024", "Month": "1", "Day": "9"}, {"Year": "2024", "Month": "2", "Day": "9"}, {"Year": "2024", "Month": "2", "Day": "25"}, {"Year": "2024", "Month": "3", "Day": "14", "Hour": "6", "Minute": "47"}, {"Year": "2024", "Month": "3", "Day": "13", "Hour": "6", "Minute": "46"}, {"Year": "2024", "Month": "3", "Day": "13", "Hour": "1", "Minute": "23"}, {"Year": "2024", "Month": "3", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["38474097", "PMC10932265", "10.3390/ijms25052850", "ijms25052850"]}}]}